SALSA MLPA KIT P060-B2 SMA

Size: px
Start display at page:

Download "SALSA MLPA KIT P060-B2 SMA"

Transcription

1 SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the older version A2, the P6-B2 probemix contains probes for exon 7 and 8 of both SMN1 as well as SMN2. SPINAL MUSCULAR ATROPHY (SMA) is a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. SMA is the second most common lethal autosomal recessive disorder in Caucasians, after cystic fibrosis. There are two (highly-similar) genes playing a pivotal role in SMA: SMN1 and SMN2. This new SALSA MLPA kit P6-B2 SMA kit will detect copy number changes of exon 7 and 8 of the SMN1 and SMN2 genes. Most individuals have two copies each of SMN1 and SMN2. The SMN1 and SMN2 genes can only be distinguished by two single nucleotide differences: one in exon 7 and one in exon 8. Both genes are located close to each other in a complicated inverted repeat area on chromosome 5q13. The two genes encode the same protein. However, the single nucleotide difference in exon 7 affects the mrna splicing. As a result, the SMN2 gene is only 1-15% as efficient in making functional SMN protein as compared to SMN1. More than 95% of SMA patients show homozygous deletion of at least exon 7 of the telomeric SMN1 gene. The great majority of SMA carriers can be identified by the presence of only a single SMN1 exon 7 copy. The one copy frequency in the US is estimated to be 1:37 for Caucasians, 1:46 for Ashkenazi Jews, 1:56 for Asians, 1:91 for African-Americans and 1:125 for Hispanics (Hendrickson, B.G. et al, 29: J.Med.Genet. 46: ). The SMN2 copy number is very variable with only 6-7% of individuals having two copies. Provided that at least one functional SMN1 copy is present, complete absence of the centromeric SMN2 gene seems to have no clinical consequences. Establishing the number of the SMN2 copy number is however important for SMA patients: the more SMN2 copies, the less severe the disease is expected to be. Absence of SMN1 combined with a SMN2 copy number of only 1 or 2 usually results in early onset severe disease. Healthy individuals lacking SMN1 but having 5 or more SMN2 copies have been described. Four probes in this P6-B2 SMA probemix detect SMN1 or SMN2 sequences. All other probes are reference probes on other chromosomes. Most important is the probe at 183 nt which is specific for SMN1 exon 7. Heterozygous deletion of this probe indicates that the individual is a SMA carrier. The SMN1 exon 8 probe at 218 nt will confirm a copy number change of the exon 7 probe in approximately 95% of all cases. Please note that only the exon 7 nucleotide difference between SMN1 and SMN2 has an effect on the production of a functional SMN protein. Therefore, in case only the SMN1 exon 8 probe appears to be deleted, it is most likely that the individual is not a SMA carrier. This new P6-B2 version also contains probes for SMN2 exon 7 (282 nt) and exon 8 (31 nt). Results from these SMN2 probes have no effect on the SMA carrier status but are important for the prognosis of SMA patients. This SALSA kit is designed to detect deletions/duplications of one or more sequences in the SMN1 and SMN2 gene in a DNA sample. Heterozygous deletions of probe recognition sequences should give a 35-5% reduced relative peak area of the amplification product of that probe. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a reduction in relative peak area, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings. Finally, note that other defects such as small point mutations will not be detected by this SALSA test. SALSA kits are sold by for research purposes and to demonstrate the possibilities of the MLPA technique. This kit is not CE/FDA certified for use in diagnostic procedures. SALSA kits are supplied with all necessary buffers and enzymes. Purchase of the SALSA test kits includes a limited license to use these products for research purposes. More information Website : info@mlpa.com (information & technical questions); order@mlpa.com (for orders) Mail : bv; Willem Schoutenstraat 6, 157 DN Amsterdam, the Netherlands SALSA kit P6 SMA page 1 of 7

2 The use of this SALSA kit requires a thermocycler with heated lid and sequence type electrophoresis equipment. Different fluorescent PCR primers are available. The MLPA technique has been first described in Nucleic Acid Research 3, e57 (22). Related SALSA kits P21 SMA: Spinal Muscular Atrophy (SMA), to determine SMN1 and SMN2 copy number changes (patients). P58 IGHMBP2: Autosomal recessive distal spinal muscular atrophy 1 (DSMA1), gene included IGHMBP2. References for MLPA used in SMA research: Yoon, S. et al. (21) determination of SMN1 and SMN2 copy numbers in a Korean population using Multiplex Ligation-dependent Probe Amplification. Korean J.Lab.Med. 3: Arkblad, E. et al (29) A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paedatr. 98: Eggermann, T. et al. (28) A new splice site mutation in the SMN1 gene causes discrepant results in SMN1 deletion screening approaches. Neuromuscul. Disord. 18: Zapletalova E. (27). Analysis of point mutations in the SMN1 gene in SMA patients bearing a single SMN1 copy. Neuromuscul Disord. 27 Apr 3. Arkblad EL. et al. (26). Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul Disord. 26 Oct 16. Scarciolla O. et al. (26). Spinal muscular atrophy genotyping by gene dosage using multiple ligationdependent probe amplification. Neurogenetics. 26 Nov;7(4): Tomaszewicz K et al. (25). Detection of homozygous and heterozygous SMN deletions in a single assay with multiplex ligation-dependent probe amplification. Beijing Da Xue Xue Bao. 18;37(1):55-7. SMN region The SMA disorder is usually divided into three clinical groups. Patients with type I SMA disease (MIM# 2533) show onset at birth or before six months, and usually die of respiratory insufficiency within two years. Type I SMA patients are never able to sit or walk. Patients with type II SMA (MIM# 25355) show onset after 6 months. They can sit but will never able to walk unaided, and life expectancy is significantly reduced. Type III SMA (MIM# 2534) patients show the first symptoms after 18 months and are able to stand and walk, but often become wheelchair-bound during youth or adulthood. The SMA region on 5q13.2, containing the telomeric SMN1 and the centromeric SMN2 genes, displays high instability, leading to frequent deletions and gene conversions. The full-length cdnas of SMN1 and SMN2 are completely identical, except for two nucleotide differences one in exon 7 and one in exon 8. The exon 8 difference has no effect on the transcript, however the exon 7 difference disrupts a putative exonic splicing enhancer in SMN2. As a result, most SMN2 transcripts lack exon 7 and are not functional. Absence of any functional SMN1 copy results in insufficient amounts of full length transcripts, and is the cause of 95% of all SMA cases. The presence of SMN2 results in a small amount of full length transcripts. The more SMN2 copies a patient has, the more functional SMN protein is produced and the milder the SMA phenotype is. The majority of type I SMA patients carry a homozygous deletion of SMN1 and a normal or reduced number of SMN2 copies. The majority of the type II and III SMA patients show homozygous absence of SMN1 and an increased number of SMN2 copies (3 4 copies). A homozygous deletion of SMN2 is found in about 5% of healthy individuals. This has no clinical phenotype when at least one functional SMN1 copy is present. Description of the SMN probes in P6-B2 SMA - The SMN1 Exon 7 probe L1781 (183 nt) is the most important probe in this probemix. This probe is specific for SMN1 and will give no significant signal on SMN2. The probe has its ligation site at the C-to-T transition in exon 7, which is a site that affects RNA splicing. The presence of SMN1 sequences (cytosine at the ligation site) in the sample will result in a peak at 183 nt. This probe can be used to determine the SMN1 copy number which is important for the determination of a SMA carrier status. Of the 5q13-linked SMA patients, 96.4% show a homozygous deletion of SMN1 exon 7 and 8, or exon 7 only. The remaining 3.6% present a compound heterozygosity with a subtle mutation on one chromosome and a deletion/gene conversion on the other. Such a subtle mutation is likely not to be detected by this P6 SMA SALSA kit P6 SMA page 2 of 7

3 MLPA test and should be identified by sequencing. In a very small number of patients the SMN1 defect is a copy number change of SMN1 exons 1-6 which may be detectable with the P21 SMA MLPA kit. - The SMN1 Exon 8 probe L1782 (218 nt) is able to distinguish between SMN1 and SMN2 at the exon 8 (G-to-A transition). The signal of this probe indicates the copy number of SMN1 exon 8. In approximately 95% of the samples, the copy number detected by the SMN1 exon 7 probe and the SMN1 exon 8 probe is identical. This SMN1 exon 8 probe cannot be used to quantify to number of SMN1 copies, as an exon 8 mutation will still result in a functional protein. Only the SMN1 exon 7 probe should be used to determine the SMN1 copy number. In the majority of the remaining 5% of the samples, gene conversion between SMN1 and SMN2 has resulted in a chimeric gene containing the SMN1 exon 7 sequence and the SMN2 exon 8 sequence. Such a hybrid gene results in a functionally identical protein as the SMN1 protein. - The SMN2 Exon 7 probe L1783 (282 nt) shows the SMN2 copy number which is important for SMA patients, but which has no influence on SMA carrier status. The SMN2 copy number is much more variable than the SMN1 copy number. Approximately 5% of individuals lack the SMN2 gene. - The SMN2 Exon 8 probe L1784 (31 nt) confirms the results obtained with the SMN2 exon 7 probe in most individuals. In case the copy number detected by this exon 8 probe does not correspond to that found by the exon 7 probe, only the exon 7 probe should be used to determine the SMN2 copy number. The summary of these findings and what they mean for carrier/patient status can be found in table 1. Table 1: Overview of expected results and the corresponding conclusion Finding Conclusion Explanation SMA symptoms - SMN1 exon 7: copies. - SMN1 exon 8: copies. confirms this. SMA symptoms - SMN1 exon 7: copies. - SMN1 exon 8: 1 or more copies. SMA symptoms - SMN1 exon 7: 1 copy. No SMA symptoms - SMN1 exon 7: 1 copy. - SMN1 exon 8: 1 copy. No SMA symptoms - SMN1 exon 7: 1 copy. - A: SMN1 exon 8 copies > 1. - B: SMN1 exon 8 copies =. No SMA symptoms - 2 copies of SMN1 exon 7. SMA patient SMN1 is absent, as no copies of the distinct SMN1 exon 7 are present. The absence of both SMN1 exon 8 copies SMA patient SMA patient SMA carrier SMA carrier Most likely not a SMA carrier False negative results SMA carrier screening SMN1 is absent, as no copies of the determining SMN1 exon 7 sequence are found. Due to gene conversion, 1 or more copies of the characteristic SMN1 exon 8 sequence appear to have become incorporated in the SMN2 gene. If the patient has SMA symptoms, but one copy of SMN1 exon 7 is present, the patient may belong to the 3.6% group presenting compound heterozygosity. Sequencing might reveal a defect in the remaining SMN1 copy. One copy of SMN1 is absent, making the person a carrier. The absence of one copy of the SMN1 exon 8 sequence confirms this. One copy of SMN1 is absent, making the person a carrier. A: due to gene conversion, 1 (or more) copies of the characteristic SMN1 exon 8 have become incorporated in the SMN2 gene. B: an SMN2 exon 8 copy has replaced the characteristic SMN1 exon 8 copy. Most likely this person is not a carrier. However, there is a possibility that both SMN1 copies lie on one chromosome. If there is reason to believe that the person is a carrier (i.e. child is SMA-patient), he/she may belong to the 4% of carriers where this is indeed the case. Be aware that for carrier screening, false negative results can be obtained. The presence of two SMN1 exon 7 copies per cell suggests that the person tested is not a carrier. However, this test result can also be due to the presence of two SMN1 copies on one chromosome and on the other, in which case the person tested is in fact a SMA carrier. Detection of some carriers is therefore compromised, as MLPA and other techniques are not able to identify carriers who have one chromosome lacking SMN1 with the other chromosome carrying two copies of SMN1. In most populations, approximately % of individuals have a chromosome 5 strand with two SMN1 copies. In some populations however, this percentage is much higher. In a recent survey (Hendrickson, B.G. SALSA kit P6 SMA page 3 of 7

4 et al, 29: J.Med.Genet. 46: ), 27% of African-Americans was shown to have three or more copies of SMN1. As a consequence, carrier testing of African-Americans is compromised as a larger number of individuals with two SMN1 copies may in fact be a carrier with two copies on the same chromosome. Therefore, one should keep in mind that a person with two SMN1 copies can STILL be a carrier: if both copies lie on one chromosome arm, there is a 5% chance that not a single SMN1 copy is passed on to the offspring. If a parent of a confirmed patient is found to have two copies, this option is a likely explanation. False positive results SMA carrier screening Please note that individual MLPA probes can be affected differently by changes in experimental procedures or impurities in samples. Highly unlikely results such as an unusual high frequency of SMN1 exon 7 loss (carrier) or SMN1 exon 7 gain, without loss or gain of the exon 8 probe in most of these samples, should be treated with caution. Data analysis The P6-B2 SMA probemix contains 21 MLPA probes with amplification products between 154 and 342 nt. In addition, it contains 9 control fragments generating an amplification product smaller than 12 nt: four DNA Quantity fragments (Q-fragments) at nt, three DNA denaturation control fragments (Dfragments) at nt, one X-fragment at 1 nt and one Y-fragment at 15 nt (QDX2). More information on how to interpret observations on these control fragments can be found in the MLPA protocol. Data generated by this probemix can be normalised intra-sample by dividing the peak area of each probe s amplification product by the total area of only the reference probes in this probemix (block normalization). Secondly, inter-sample normalisation can be achieved by dividing the intra-normalised probe ratio in a sample by the average intra-normalised probe ratio of all reference samples. Please note that this type of normalization assumes that no changes occurred in the genomic regions targeted by the reference probes. Data normalisation should be performed within one experiment. Only samples purified by the same method should be compared. Confirmation of most exons deletions and amplifications can be done by e.g. Southern blots or long range PCR. Note that Coffalyser, the MLPA analysis tool developed at, can be downloaded free of charge from our website Reference samples The choice of reference samples is important for the correct determination of the SMN1 and SMN2 copy numbers. is not able to provide reference DNA samples. One reason is that MLPA reactions on all samples, including reference samples, should be done on DNA extracted by the same method. It is strongly advised to first make a selection of suitable reference samples with known copy numbers before SMA testing is started. One method of doing this is to test a number (e.g. 16) of healthy individuals. Identification of samples having two copies of both SMN1 and SMN2 should usually be simple as in most populations these will constitute the great majority of the samples. Please note that in some populations, such as African-Americans, the number of individuals with a total of three SMN1 copies may be almost identical to that with two copies (Hendrickson, B.G. et al, 29: J.Med.Genet. 46: ). This product was developed at. Info/remarks/suggestions for improvement: info@mlpa.com. SALSA kit P6 SMA page 4 of 7

5 Table 2. SALSA MLPA P6-B2 SMA probemix Length Chromosomal position SALSA MLPA probe (nt) reference SMN1 / SMN Q-fragments: DNA quantity; only visible with less than 1 ng sample DNA D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete denaturation 1 X-fragment: Specific for the X chromosome 15 Y-fragment: Specific for the Y chromosome 154 Reference probe 2595-L1785 5q Reference probe 2291-L1786 3p Reference probe 2978-L1787 4q SMN1 probe L1781 SMN1 exon Reference probe 559-L q22 2 Reference probe 976-L p13 28 Reference probe 1249-L1796 1q SMN1 probe L1782 SMN1 exon Reference probe L1711 2p Reference probe 2334-L q Reference probe L171 15q Reference probe L1799 9q Reference probe 763-L1791 1q Reference probe L1798 4q SMN2 probe L1783 SMN2 exon 7 292~ Reference probe 824-L1797 3q25 31 SMN2 probe L1784 SMN2 exon Reference probe 6425-L1792 6p Reference probe 142-L1793 8q Reference probe 143-L1794 8q Reference probe L q12 ~ This probe has been reported to be more variable. Table 3. SMN1 and SMN2 probes in P6-B2 Length SALSA Partial sequence (24 nt Distance to Gene / Exon (nt) MLPA probe adjacent to ligation site) next probe 183 ٨ L1781 SMN1 exon 7 TTACAGGGTTTC-AGACAAAATCAA.7 kb L1782 SMN1 exon 8 GTAAAAGACTGG-GGTGGGGGTGGG > 1 kb L1783 SMN2 exon 7 TTACAGGGTTTT-AGACAAAATCAA.7 kb L1784 SMN2 exon 8 GTAAAAGACTGA-GGTGGGGGTGGG ٨ One copy in most carriers; none in most patients. + Confirms SMN1 exon 7 results in 95 % of carriers. Note: The identity of the genes detected by the reference probes and the complete probe sequences are available on request: info@mlpa.com. Please notify us of any mistakes: info@mlpa.com. SALSA kit P6 SMA page 5 of 7

6 Description version 15; SALSA MLPA P6 SMA sample pictures Figure 1. Capillary electrophoresis pattern of a sample of approximately 5 ng human male control DNA (2 copies each of SMN1 and SMN2) analyzed with SALSA MLPA kit P6-B1 SMA (lot 21) Figure 2. Capillary electrophoresis pattern of a sample of approximately 5 ng human male SMA-carrier (1x SMN1, 2x SMN2) DNA analyzed with SALSA MLPA kit P6-B1 SMA (lot 21) Figure 3. Capillary electrophoresis pattern of a sample of approximately 5 ng human female DNA (3x SMN1, 1x SMN2) analyzed with SALSA MLPA kit P6-B1 SMA (lot 21) Figure 4. Capillary electrophoresis pattern of a sample of approximately 5 ng human male DNA (4x SMN1; x SMN2) analyzed with SALSA MLPA kit P6-B1 SMA (lot 21). SALSA kit P6 SMA page 6 of 7

7 SALSA MLPA kit P6-B2 SMA sample picture D ye Sign al Figure 1. Capillary electrophoresis pattern of a sample of approximately 5 ng human male control DNA analyzed with SALSA MLPA kit P6-B2 SMA (lot 111). Implemented changes - compared to the previous product description version. Version 15 (46) - Product description adapted to a new lot (lot number added, new picture included). Version 14 (46) - Product description adapted to a new product version (version number changed, lot number added, explanation of changes as compared to the previous version on page 1). New sample picture added. - Warning added in Table 1, 292 nt probe 824-L1797. Version 13 (45) - Product description adapted to a new product lot (version number changed, lot number added). Version 12 (45) - Product description adapted to a new product version (version number changed, lot number added, changes in Table 1 and Table 2, new pictures included). - Major changes in the text of this complete product description. SALSA kit P6 SMA page 7 of 7

MRC-Holland MLPA. Description version 19;

MRC-Holland MLPA. Description version 19; SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL

More information

MRC-Holland MLPA. Description version 08; 30 March 2015

MRC-Holland MLPA. Description version 08; 30 March 2015 SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.

More information

SALSA MLPA KIT P050-B2 CAH

SALSA MLPA KIT P050-B2 CAH SALSA MLPA KIT P050-B2 CAH Lot 0510, 0909, 0408: Compared to lot 0107, extra control fragments have been added at 88, 96, 100 and 105 nt. The 274 nt probe gives a higher signal in lot 0510 compared to

More information

MRC-Holland MLPA. Description version 14; 28 September 2016

MRC-Holland MLPA. Description version 14; 28 September 2016 SALSA MLPA probemix P279-B3 CACNA1A Lot B3-0816. As compared to version B2 (lot B2-1012), one reference probe has been replaced and the length of several probes has been adjusted. Voltage-dependent calcium

More information

MRC-Holland MLPA. Description version 12; 13 January 2017

MRC-Holland MLPA. Description version 12; 13 January 2017 SALSA MLPA probemix P219-B3 PAX6 Lot B3-0915: Compared to version B2 (lot B2-1111) two reference probes have been replaced and one additional reference probe has been added. In addition, one flanking probe

More information

MRC-Holland MLPA. Description version 07; 26 November 2015

MRC-Holland MLPA. Description version 07; 26 November 2015 SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced

More information

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix. SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:

More information

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted. mix P169-C2 HIRSCHSPRUNG-1 Lot C2-0915. As compared to version C1 (lot C1-0612), the length of one has been adjusted. Hirschsprung disease (HSCR), or aganglionic megacolon, is a congenital disorder characterised

More information

MRC-Holland MLPA. Description version 29;

MRC-Holland MLPA. Description version 29; SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,

More information

MRC-Holland MLPA. Description version 08; 18 November 2016

MRC-Holland MLPA. Description version 08; 18 November 2016 SALSA MLPA probemix P122-D1 NF1 AREA Lot D1-1016. As compared to lot C2-0312, four probes in the NF1 area and one reference probe have been removed, four reference probes have been replaced and several

More information

MRC-Holland MLPA. Description version 30; 06 June 2017

MRC-Holland MLPA. Description version 30; 06 June 2017 SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are

More information

MRC-Holland MLPA. Description version 29; 31 July 2015

MRC-Holland MLPA. Description version 29; 31 July 2015 SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082

More information

MRC-Holland MLPA. Description version 18; 09 September 2015

MRC-Holland MLPA. Description version 18; 09 September 2015 SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the

More information

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced.

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced. mix P241-D2 MODY mix 1 Lot D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent diabetes

More information

MRC-Holland MLPA. Description version 13;

MRC-Holland MLPA. Description version 13; SALSA MLPA probemix P027-C1 Uveal Melanoma Lot C1-0211: A large number of probes have been replaced by other probes in the same chromosomal regions as compared to previous lots, and several reference probes

More information

MRC-Holland MLPA. Description version 06; 23 December 2016

MRC-Holland MLPA. Description version 06; 23 December 2016 SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated

More information

SALSA MLPA probemix P315-B1 EGFR

SALSA MLPA probemix P315-B1 EGFR SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional

More information

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced.

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced. mix P241-D2 MODY mix 1 Lot D2-0716, D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent

More information

P323-B1 CDK4-HMGA2-MDM2

P323-B1 CDK4-HMGA2-MDM2 SALSA MLPA probemix P323-B1 CDK4-HMGA2-MDM2 Lot B1-0714, B1-0711. As compared to previous test version (lot A1-0508), this probemix has been completely redesigned. Probes for HMGA2 and several other genes

More information

SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B

SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B1-0613. The purpose of the P372 probemix is to further investigate results found with the P245 Microdeletion Syndromes-1A probemix. The

More information

MRC-Holland MLPA. Description version 06; 07 August 2015

MRC-Holland MLPA. Description version 06; 07 August 2015 SALSA MLPA probemix P323-B1 CDK4-HMGA2-MDM2 Lot B1-0711. As compared to version A1 (test version sent to test labs), this product has been completely redesigned. Probes for HMGA2 and several other genes

More information

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment).

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment). SALSA MLPA probemix P343-C3 Autism-1 Lot C3-1016. As compared to version C2 (lot C2-0312) five reference probes have been replaced, one reference probe added and several lengths have been adjusted. Warning:

More information

MRC-Holland MLPA. Description version 08; 07 May 2015

MRC-Holland MLPA. Description version 08; 07 May 2015 mix P185-C1 Intersex Lot C1-0611: As compared to the previous version B2 (lot B2-0311), s for CYP21A2 have been removed and s for the CXorf21 gene as well as additional s for NR0B1, NR5A1 and the Y chromosome

More information

SALSA MLPA probemix P371-A1 Microdeletion Syndromes 5 Lot A1-0509

SALSA MLPA probemix P371-A1 Microdeletion Syndromes 5 Lot A1-0509 mix P371-A1 Microdeletion Syndromes 5 Lot A1-0509 The purpose of the P371 mix is to further investigate results found with the P245 Microdeletion mix. The P245 mix provides a possibility to screen samples

More information

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted.

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted. mix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four s have been adjusted. The sex-determining region on chromosome Y (SRY) is the most important

More information

SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A

SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A1-1011. This SALSA MLPA probemix is for basic research and intended for experienced MLPA users only! This probemix enables you to quantify genes

More information

SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407

SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407 SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407 The Mismatch Repair (MMR) system is critical for the maintenance of genomic stability. MMR increases the fidelity of DNA

More information

MRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53.

MRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53. SALSA MLPA probemix P056-C1 TP53 Lot C1-0215 & lot C1-0214. As compared to version B1 (lot B1-1011) most of the reference and flanking probes have been replaced and several have been added. Furthermore,

More information

SALSA MLPA KIT P078-B1 Breast Tumour Lot 0210, 0109

SALSA MLPA KIT P078-B1 Breast Tumour Lot 0210, 0109 SALSA MLPA KIT P078-B1 Breast Tumour Lot 0210, 0109 This P078-B1 Breast Tumour probemix contains probes for several genes (including ERBB2, BIRC5, MYC, TOP2A, ESR1, MTDH, CCND1, CCNE1, EGFR and C11orf30)

More information

PRADER WILLI/ANGELMAN

PRADER WILLI/ANGELMAN SALSA MS-MLPA probemix ME028-B2 PRADER WILLI/ANGELMAN Lot B2-0811: As compared to version B1 (lot B1-0609, B1-1108), the 88 and 96 nt control fragments have been replaced (QDX2). PRADER-WILLI SYNDROME

More information

MRC-Holland MLPA. Description version 52; 22 July 2015

MRC-Holland MLPA. Description version 52; 22 July 2015 SALSA MS-MLPA probemix ME028-B2 Prader-Willi/Angelman Lot B2-0413, lot B2-0811. As compared to version B1 (lot B1-0609), the control fragments have been replaced (QDX2). PRADER-WILLI SYNDROME (PWS) and

More information

SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B

SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B1-0916 and B1-0713. Copy number changes of the human chromosome 8 are common in many types of tumours. In most cases, losses of 8p sequences and gains of 8q

More information

SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.

SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. This SALSA probemix is for basic research only! This

More information

MRC-Holland MLPA. Description version 23; 15 February 2018

MRC-Holland MLPA. Description version 23; 15 February 2018 SALSA MLPA probemix P225-D2 PTEN Lot D2-0315. As compared to the previous version (lot D1-0613), one probe has a small change in length but no change in the sequence detected. PTEN is a tumour suppressor

More information

SALSA MLPA probemix P383-A1 T-ALL Lot A

SALSA MLPA probemix P383-A1 T-ALL Lot A SALSA MLPA probemix P383-A1 T-ALL Lot A1-0213. T-lineage acute lymphoblastic leukaemia (T-ALL) is a clonal malignant disorder of immature T-cells, which accounts for about 15% of paediatric and 25% of

More information

MRC-Holland MLPA. Description version 05; 03 April 2019

MRC-Holland MLPA. Description version 05; 03 April 2019 SALSA MLPA probemix ME012-A1 MGMT-IDH1-IDH2 Lot A1-1215. Glioblastoma, the most common malignant primary brain tumour, is characterised by aggressive behaviour and a poor survival. Hypermethylation in

More information

Product Description SALSA MLPA Probemix P055-D1 PAH To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P055-D1 PAH To be used with the MLPA General Protocol. Product Description SALSA Probemix P055-D1 PAH To be used with the MLPA General Protocol. Version D1. For complete product history see page 7. Catalogue numbers: P055-025R: SALSA MLPA probemix P055 PAH,

More information

Product Description SALSA MLPA Probemix P027-C2 Uveal melanoma To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P027-C2 Uveal melanoma To be used with the MLPA General Protocol. Product Description SALSA Probemix P027-C2 Uveal melanoma To be used with the MLPA General Protocol. Version C2. As compared to version C1, three reference probes have been replaced and the lengths of

More information

Product Description SALSA MLPA Probemix P138-C1 SLC2A1-STXBP1 To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P138-C1 SLC2A1-STXBP1 To be used with the MLPA General Protocol. Product Description SALSA Probemix P138-C1 SLC2A1-STXBP1 To be used with the MLPA General Protocol. Version C1. For complete product history see page 7. Catalogue numbers: P138-025R: SALSA MLPA probemix

More information

Product Description SALSA MLPA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol.

Product Description SALSA MLPA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Product Description SALSA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Version C1. As compared to version B3, the probes for the BRCA2 upstream region and exons 8, 11, 12, 19

More information

MRC-Holland MLPA. Description version 28; 4 January 2018

MRC-Holland MLPA. Description version 28; 4 January 2018 SALSA MLPA probemix ME011-B3 Mismatch Repair genes Lot B3-1017 and B3-0715. As compared to the previous version B2 (lot B2-0614), one probe has a small change in length but no change in the sequence detected.

More information

Association of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4

Association of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4 jnnp-2016-314292 1 - SUPPLEMENTARY FILE - Methods and additional data on clinical characteristics and motor development Association of motor milestones and SMN2 copy and outcome in spinal muscular atrophy

More information

MRC-Holland MLPA. Description version 23; 26 January 2017

MRC-Holland MLPA. Description version 23; 26 January 2017 SALSA MLPA probemix ME024-B2 9p21 CDKN2A/2B region Lot B2-0615. As compared to the previous version B1 (lot B1-0411), one flanking probe is redesigned, two reference probes are replaced, and several probes

More information

MRC-Holland MLPA. Description version 10; 06 April 2018

MRC-Holland MLPA. Description version 10; 06 April 2018 Description version ; 6 April 8 mix P36-B Y-Chromosome Microdeletions Lot B-5. As compared to version A (Lot A-), all probes f DPY9L, one probe f RBMYCP and one probe f KDM5D have been removed, and one

More information

Product Description SALSA MS-MLPA Probemix ME028-C1 Prader-Willi/Angelman To be used with the MS-MLPA General Protocol.

Product Description SALSA MS-MLPA Probemix ME028-C1 Prader-Willi/Angelman To be used with the MS-MLPA General Protocol. Product Description SALSA MS- Probemix ME028-C1 Prader-Willi/Angelman To be used with the MS-MLPA General Protocol. Version C1. For complete product history see page 9. Catalogue numbers: ME028-025R: SALSA

More information

SALSA MLPA KIT P036-E1 HUMAN TELOMERE-3 Lot 0808: As compared to the previous version (P036-D2), the probes for 1p and 4q have been replaced.

SALSA MLPA KIT P036-E1 HUMAN TELOMERE-3 Lot 0808: As compared to the previous version (P036-D2), the probes for 1p and 4q have been replaced. SALSA MLPA KIT P036-E1 HUMAN TELOMERE-3 Lot 0808: As compared to the previous version (P036-D2), the probes for 1p and 4q have been replaced. MENTAL RETARDATION is caused by aberrant copy numbers of subtelomeric

More information

MRC-Holland MLPA. Description version 15;

MRC-Holland MLPA. Description version 15; probemix P036-E1 HUMAN TELOMERE-3 Lot E1-0910, E1-1208, E1-0808. As compared to version D2 (lot D2-0408), the probes for 1p and 4q have been replaced. Approximately 3-8% of all cases of mental retardation

More information

Product Description SALSA MS-MLPA Probemix ME011-C1 Mismatch Repair Genes To be used with the MS-MLPA General Protocol.

Product Description SALSA MS-MLPA Probemix ME011-C1 Mismatch Repair Genes To be used with the MS-MLPA General Protocol. Product Description SALSA MS- Probemix ME011-C1 Mismatch Repair Genes To be used with the MS-MLPA General Protocol. Version C1. As compared to the previous version (lot B3-1017), this probemix has been

More information

Product Description SALSA MLPA Probemix P015-F2 MECP2 To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P015-F2 MECP2 To be used with the MLPA General Protocol. Product Description SALSA Probemix P015-F2 MECP2 To be used with the MLPA General Protocol. Version F2. Compared to version F1, two reference probes have been replaced and the 118 nt Y fragment has been

More information

Product Description SALSA MLPA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Product Description SALSA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Version C1. As compared to version B3, the probes for the BRCA2 upstream region and exons 8, 11, 12, 19

More information

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647 Ordering Practice Jane Smith John Smith Practice Code: 675 Miller MD 374 Broadway New York, NY 10000 Physician: Dr. Frank Miller Report Generated: 2016-02-03 DOB: 1973-02-19 Gender: Female Ethnicity: European

More information

Screening for spinal muscular atrophy External review against programme appraisal criteria for the UK National Screening Committee (UK NSC)

Screening for spinal muscular atrophy External review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Screening for spinal muscular atrophy External review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version: Third Draft Consultation Author: Costello Medical Date:

More information

Muscular Dystrophy. Biol 405 Molecular Medicine

Muscular Dystrophy. Biol 405 Molecular Medicine Muscular Dystrophy Biol 405 Molecular Medicine Duchenne muscular dystrophy Duchenne muscular dystrophy is a neuromuscular disease that occurs in ~ 1/3,500 male births. The disease causes developmental

More information

SMA IS A SEVERE NEUROLOGICAL DISORDER [1]

SMA IS A SEVERE NEUROLOGICAL DISORDER [1] SMA OVERVIEW SMA IS A SEVERE NEUROLOGICAL DISORDER [1] Autosomal recessive genetic inheritance 1 in 50 people (approximately 6 million Americans) are carriers [2] 1 in 6,000 to 1 in 10,000 children born

More information

Product Description SALSA MLPA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Product Description SALSA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Version D1. For a complete product history see page 11. Catalogue numbers: P002-025R: SALSA MLPA probemix P002

More information

The Meaning of Genetic Variation

The Meaning of Genetic Variation Activity 2 The Meaning of Genetic Variation Focus: Students investigate variation in the beta globin gene by identifying base changes that do and do not alter function, and by using several CD-ROM-based

More information

Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome

Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome It s about knowing. Prenatal testing is not about telling you what s wrong, it s knowing that everything is

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018

More information

Spinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting

Spinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting Spinal Muscular Atrophy: Case Study Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting approximately one in 6,000 babies. It is estimated that one in every 40 Americans carries

More information

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant

More information

Should Universal Carrier Screening be Universal?

Should Universal Carrier Screening be Universal? Should Universal Carrier Screening be Universal? Disclosures Research funding from Natera Mary E Norton MD University of California, San Francisco Antepartum and Intrapartum Management June 15, 2017 Burden

More information

Product Description SALSA MLPA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol.

Product Description SALSA MLPA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Product Description SALSA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Version D1. As compared to version C2, 12 extra BRCA1 probes and 3 probes for exon 24 have been included, and

More information

(SMN1), which is found in the lower part of the spinal cord. 1 There are several different types of

(SMN1), which is found in the lower part of the spinal cord. 1 There are several different types of SMA and the role of the Survival Motor Neuron 1 Gene Jacqueline Seals Copyright May, 2015, Jacqueline Seals and Koni Stone Spinal muscular atrophy (SMA) is one of the leading causes of infant mortality.

More information

Prenatal diagnosis for risk of spinal muscular atrophy

Prenatal diagnosis for risk of spinal muscular atrophy BJOG: an International Journal of Obstetrics and Gynaecology November 2002, Vol. 109, pp. 1244 1249 Prenatal diagnosis for risk of spinal muscular atrophy I. Cuscó a, M.J. Barceló a, C. Soler a, J. Parra

More information

BIOL2005 WORKSHEET 2008

BIOL2005 WORKSHEET 2008 BIOL2005 WORKSHEET 2008 Answer all 6 questions in the space provided using additional sheets where necessary. Hand your completed answers in to the Biology office by 3 p.m. Friday 8th February. 1. Your

More information

Genetics and Reproductive Options for SMA Families Annual SMA Conference Dallas, Texas Friday, June 15, 2017

Genetics and Reproductive Options for SMA Families Annual SMA Conference Dallas, Texas Friday, June 15, 2017 Genetics and Reproductive Options for SMA Families 2018 Annual SMA Conference Dallas, Texas Friday, June 15, 2017 Part 1: SMA and Genetics Louise R Simard, PhD Part 2: SMA Carrier Screening Melissa Gibbons,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy

More information

Introduction to Genetics

Introduction to Genetics Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist

More information

1" 7I'?? 1" : t"i"i"itf

1 7I'?? 1 : tiiitf Cell, Vol. 80, 1-5, January 13, 1995, Copyright 1995 by Cell Press Genes for SMA: Multum In Parvo Minireview Benjamin Lewin Cell In this issue of Ceil, we take the unusual step of publishing two articles

More information

Improving detection and genetic counseling in carriers of spinal muscular atrophy

Improving detection and genetic counseling in carriers of spinal muscular atrophy Clin Genet 2014: 85: 470 475 Printed in Singapore. All rights reserved Short Report 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12222 Improving detection

More information

MODULE NO.14: Y-Chromosome Testing

MODULE NO.14: Y-Chromosome Testing SUBJECT Paper No. and Title Module No. and Title Module Tag FORENSIC SIENCE PAPER No.13: DNA Forensics MODULE No.21: Y-Chromosome Testing FSC_P13_M21 TABLE OF CONTENTS 1. Learning Outcome 2. Introduction:

More information

Nusinersen Use in Spinal Muscular Atrophy

Nusinersen Use in Spinal Muscular Atrophy Nusinersen Use in Spinal Muscular Atrophy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Slide 1 Evidence in Focus Endorsement and

More information

Genetic Disorders. and. blood vessels the and. How many genes are affected by this deletion? Turner s Syndrome- An incomplete or missing chromosome

Genetic Disorders. and. blood vessels the and. How many genes are affected by this deletion? Turner s Syndrome- An incomplete or missing chromosome Genetic Disorders A genetic disorder is an abnormality in the. They can range for a deletion of a gene to the deletion of an entire chromosome. List the types of genetic disorders. Williams Syndrome- A

More information

MULTIPLE CHOICE QUESTIONS

MULTIPLE CHOICE QUESTIONS SHORT ANSWER QUESTIONS-Please type your awesome answers on a separate sheet of paper. 1. What is an X-linked inheritance pattern? Use a specific example to explain the role of the father and mother in

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2018 10/2019 10/2018 Description of Procedure or Service Spinal muscular atrophy

More information

HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007

HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007 MIT OpenCourseWare http://ocw.mit.edu HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.

More information

The Biology and Genetics of Cells and Organisms The Biology of Cancer

The Biology and Genetics of Cells and Organisms The Biology of Cancer The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried

More information

Lab Activity Report: Mendelian Genetics - Genetic Disorders

Lab Activity Report: Mendelian Genetics - Genetic Disorders Name Date Period Lab Activity Report: Mendelian Genetics - Genetic Disorders Background: Sometimes genetic disorders are caused by mutations to normal genes. When the mutation has been in the population

More information

Chromosome Structure & Recombination

Chromosome Structure & Recombination Chromosome Structure & Recombination (CHAPTER 8- Brooker Text) April 4 & 9, 2007 BIO 184 Dr. Tom Peavy Genetic variation refers to differences between members of the same species or those of different

More information

5/2/18. After this class students should be able to: Stephanie Moon, Ph.D. - GWAS. How do we distinguish Mendelian from non-mendelian traits?

5/2/18. After this class students should be able to: Stephanie Moon, Ph.D. - GWAS. How do we distinguish Mendelian from non-mendelian traits? corebio II - genetics: WED 25 April 2018. 2018 Stephanie Moon, Ph.D. - GWAS After this class students should be able to: 1. Compare and contrast methods used to discover the genetic basis of traits or

More information

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our 1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented

More information

Population Screening for Fragile X Syndrome

Population Screening for Fragile X Syndrome Population Screening for Fragile X Syndrome FLORA TASSONE PH.D. DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR MEDICINE AND MIND INSTITUTE UC DAVIS, CALIFORNIA USA Molecular Pathology: Principles in Clinical

More information

Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report

Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report Roshanak Jazayeri, MD, PhD Assistant Professor of Medical Genetics Faculty of Medicine, Alborz University of Medical Sciences

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)

More information

Original Policy Date

Original Policy Date MP 2.04.76 Genetic Counseling Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created Local Policy/ 12:2013 Return to Medical Policy Index Disclaimer

More information

Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1

Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1 Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1 17 th April 2018 Adnan Manzur Consultant Paediatric Neurologist Dubowitz Neuromuscular Centre, GOSH & ICH,

More information

AIDS - Knowledge and Dogma. Conditions for the Emergence and Decline of Scientific Theories Congress, July 16/ , Vienna, Austria

AIDS - Knowledge and Dogma. Conditions for the Emergence and Decline of Scientific Theories Congress, July 16/ , Vienna, Austria AIDS - Knowledge and Dogma Conditions for the Emergence and Decline of Scientific Theories Congress, July 16/17 2010, Vienna, Austria Reliability of PCR to detect genetic sequences from HIV Juan Manuel

More information

Single Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions

Single Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions Single Gene (Monogenic) Disorders Mendelian Inheritance: Definitions A genetic locus is a specific position or location on a chromosome. Frequently, locus is used to refer to a specific gene. Alleles are

More information

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)

More information

The Human Major Histocompatibility Complex

The Human Major Histocompatibility Complex The Human Major Histocompatibility Complex 1 Location and Organization of the HLA Complex on Chromosome 6 NEJM 343(10):702-9 2 Inheritance of the HLA Complex Haplotype Inheritance (Family Study) 3 Structure

More information

Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy

Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy TEMPLATE Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Date: [Insert Name of Medical Director] RE: Patient Name [ ] [Insurance Company] Policy Number [ ] [Address]

More information

Product Description SALSA MLPA Probemix P250-B2 DiGeorge To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P250-B2 DiGeorge To be used with the MLPA General Protocol. Product Description SALSA Probemix P250-B2 DiGeorge To be used with the MLPA ral Protocol. Version B2. As compared to version B1, the control fragments have been adjusted. For complete product history

More information

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi 2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000

More information

Figure 1: Transmission of Wing Shape & Body Color Alleles: F0 Mating. Figure 1.1: Transmission of Wing Shape & Body Color Alleles: Expected F1 Outcome

Figure 1: Transmission of Wing Shape & Body Color Alleles: F0 Mating. Figure 1.1: Transmission of Wing Shape & Body Color Alleles: Expected F1 Outcome I. Chromosomal Theory of Inheritance As early cytologists worked out the mechanism of cell division in the late 1800 s, they began to notice similarities in the behavior of BOTH chromosomes & Mendel s

More information

variant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still

variant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still 157 Neurological disorders primarily affect and impair the functioning of the brain and/or neurological system. Structural, electrical or metabolic abnormalities in the brain or neurological system can

More information

Extra Review Practice Biology Test Genetics

Extra Review Practice Biology Test Genetics Mendel fill in the blanks: Extra Review Practice Biology Test Genetics Mendel was an Austrian monk who studied genetics primarily using plants. He started with plants that produced offspring with only

More information

MRC-Holland MLPA. Description version 24;

MRC-Holland MLPA. Description version 24; SALSA MLPA KIT P245-A2 Microdeletion Syndromes-1 Lot 0909, 0209, 1008. As compared to lot 1207, two extra control fragments at 100 and 105 nt have been added (X and Y-specific). The 108 nt Y probe has

More information

Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report of Four Novel Mutations

Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report of Four Novel Mutations Korean J Lab Med 2010;30:190-4 DOI 10.3343/kjlm.2010.30.2.190 Original Article Diagnostic Genetics Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report

More information

DMD Genetics: complicated, complex and critical to understand

DMD Genetics: complicated, complex and critical to understand DMD Genetics: complicated, complex and critical to understand Stanley Nelson, MD Professor of Human Genetics, Pathology and Laboratory Medicine, and Psychiatry Co Director, Center for Duchenne Muscular

More information

Differences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients

Differences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients (2014) 59, 46 50 & 2014 The Japan Society of Human Genetics All rights reserved 1434-5161/14 www.nature.com/jhg OPEN ORIGINAL ARTICLE Differences in carrier frequency between mothers of Duchenne and Becker

More information